5-HT 1F Inhibitors
3 drugsAbout 5-HT 1F
The 5-HT1F receptor is a serotonin receptor subtype expressed in the central nervous system. It is implicated in neuronal signaling and has been explored as a drug target for CNS conditions.
Human genetic studies provide moderate support for 5-HT1F as a therapeutic target, with variants linked to prostate carcinoma (score 0.55) and intestinal disease (score 0.53). Colocalization analysis reveals 20 strong eQTL/pQTL signals.
5-HT1F is targeted by 3 FDA-approved small molecule drugs, including ELETRIPTAN HYDROBROMIDE (Relpax) and ALMOTRIPTAN MALATE, all indicated for CNS conditions. Chartwell RX, Upjohn, and Ajanta Pharma Ltd. are key players in this space.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Untreated Follicular Lymphoma with only 1 trials.
5-HT 1F Genetic Evidence Moderate
Genetic evidence offers moderate support, with a maximum score of 0.55 linking HTR1F to prostate carcinoma.
Further investigation of the top genetic associations could reveal novel therapeutic opportunities.
Evidence Across Diseases
20 totalGWAS and other genetic studies link HTR1F to 26 diseases.
🔗 Colocalization Evidence 20 strong
max H4: 0.99eQTL/pQTL signals for HTR1F colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top 5-HT 1F Drugs
Chartwell RX, Upjohn, and Ajanta Pharma Ltd. are the companies with approved 5-HT1F targeting drugs.
The relatively unconcentrated market suggests opportunities for new entrants with differentiated products.
5-HT 1F Drug Modality Landscape
Modalities
Routes of Administration
5-HT 1F is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or biologics could provide a competitive advantage.
5-HT 1F Clinical Trials 1 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
5-HT 1F Drug Approval Timeline (2002 - 2017)
The first drug was approved in 2002 (Relpax), and the most recent in 2017 (ELETRIPTAN HYDROBROMIDE).
The approval timeline indicates a potentially maturing market, requiring innovative strategies for future success.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (12 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 13 clinical trials targeting 5-HT 1F.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities